 CAMBRIDGE, Mass. and NEW YORK, March 10, 2021 GLOBE NEWSWIRE -- Black Diamond Therapeutics, Inc. Nasdaq: BDTX, a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on BDTX-189 and BDTX-1535 will be presented as late-breaking poster presentations at the American Association for Cancer Research AACR Virtual Annual Meeting, taking place April 10-15, 2021. 